The Department of Health and Human Services yesterday took action to provide a pathway for all states and territories to increase access to critical COVID-19 monoclonal antibody therapeutics. HHS executed an amendment to the Public Readiness and Emergency Preparedness Act Declaration that expands the pool of professionals now covered under the PREP Act for the administration of COVID-19 monoclonal antibody therapeutics. Specifically, the amendment includes coverage of licensed pharmacists, pharmacy technicians, and pharmacy interns when administering COVID-19 monoclonal antibody therapeutics orally, through intramuscular injection, or through subcutaneous injection. The provision was included as part of President Biden’s COVID-19 action plan released yesterday. For details on other provisions included in the action plan and AHA’s reaction, see yesterday’s Special Bulletin.

Related News Articles

Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…